NEW YORK (TheStreet) -- Shares of Tekmira Pharmaceuticals (TKMR) surged 11.65% to $15.52 in afternoon trading Wednesday after the company provided an update on its Phase I/II clinical study of its treatment TKM-PLK1 in patients with advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) and Adrenocortical Carcinoma (ACC).
Tekmira announced it had completed the enrollment of the target patient numbers in these studies. The company has treated 55 patients to date, and 31 of these are part of the target population of GI-NET or ACC patients. Nine GI-NET and ACC patients remain actively on treatment, and the company is continuing to collect data.
Tekmira said it sees indications of anti-tumor activity in some of the treated subjects, and one ACC patient showed an almost complete resolution of the disease.
Exclusive Report: Jim Cramer’s Best Stocks for 2015
The company said it expects final data from these studies in mid-2015.
More than 2.9 million shares had changed hands as of 2:37 p.m., compared to the daily average volume of 2,631,800.TKMR data by YCharts